- Home
- REAL vs ZURA Comparison
REAL vs ZURA Comparison
Compare REAL & ZURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | REAL | ZURA |
|---|---|---|
| Founded | 2011 | 2022 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 252.9M |
| IPO Year | 2019 | N/A |
Fundamental Metrics
Financial Performance| Metric | REAL | ZURA |
|---|---|---|
| Price | $15.74 | $5.54 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 8 |
| Target Price | ★ $15.71 | $11.38 |
| AVG Volume (30 Days) | ★ 2.5M | 589.2K |
| Earning Date | 02-19-2026 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $662,789,000.00 | N/A |
| Revenue This Year | $17.10 | N/A |
| Revenue Next Year | $10.90 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 14.30 | N/A |
| 52 Week Low | $4.61 | $0.97 |
| 52 Week High | $16.74 | $5.75 |
Technical Indicators
Market Signals| Indicator | REAL | ZURA |
|---|---|---|
| Relative Strength Index (RSI) | 60.98 | 79.70 |
| Support Level | $15.81 | $5.07 |
| Resistance Level | $16.74 | $5.62 |
| Average True Range (ATR) | 0.78 | 0.37 |
| MACD | -0.00 | 0.13 |
| Stochastic Oscillator | 63.79 | 88.77 |
Price Performance
Historical ComparisonAbout REAL The RealReal Inc.
The RealReal is the largest pure-play luxury resale platform in the US, generating $1.8 billion in 2024 gross merchandise volume and addressing a niche (personal luxury resale) that had previously been serviced by inefficient upscale boutiques and local pawn shops. The company generates revenue via consignment and first-party sales on its online marketplace, and through a small volume of direct sales. With a hands-on approach that actively sources inventory and authenticates every item on its platform, The RealReal is able to justify much higher take rates than peers, working out to roughly 36% of net merchandise value in 2024, which excludes returns, cancellations, and first-party sales.
About ZURA Zura Bio Limited
Zura Bio Ltd is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. It is developing three assets which have completed Phase I/Ib studies and are Phase II ready. It is developing a portfolio of therapeutic indications for tibulizumab and torudokimab with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases.